Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer. (PRO2)
Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer During Chemotherapy in Combination With HER2-targeted Therapy (Including Tyrosine Kinase Inhibitors [TKI]) or an Antibody-drug Conjugate Therapy: a Multicenter Randomized Controlled Trial.
Sponsor: Mobile Health AG
Terminated
The study was discontinued due to low recruitment rates. Despite various measures, such as training courses and workshops, recruitment rates could not be improved in the long term.
Other Breast Cancer trials with similar outcome
Listed as NCT05425550, this NA trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Mobile Health AG, it has been updated 10 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Apr 2025 — Oct 2025 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Apr 2025 [monthly]
Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Sep 2023 — Jul 2024 [monthly]
Recruiting NA
-
May 2023 — Sep 2023 [monthly]
Recruiting NA
-
Jan 2023 — May 2023 [monthly]
Recruiting NA
-
Sep 2022 — Jan 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mobile Health AG
- Palleos Healthcare GmbH
For direct contact, visit the study record on ClinicalTrials.gov .